Jul 29 2004
Corus Pharma announced yesterday that it has been selected as a member of FierceBiotech's annual "The Fierce 15." FierceBiotech Editor-in-Chief John D. Carroll observed "We applaud Corus' ongoing commitment to increasing the quality of life for people living with cystic fibrosis."
Corus 1020 (aztreonam formulated for inhalation) is an antibiotic that has a broad spectrum of activity against Gram-negative bacteria which are commonly found in lung infections in cystic fibrosis patients. The product has been specifically formulated to try to improve airway tolerability and will be delivered directly to the lung to increase the concentration of the drug at the site of infection.
"FierceBiotech is a respected publication," said Jonathan P. Mow, Vice President of Commercial Operations for Corus Pharma. "We are pleased to have been selected in this year's group."
This year's "Fierce 15" list also includes a Massachusetts company that is developing implantable bionics for the severely disabled, a German company developing antibody-based cancer treatments, a California company that is making inroads on the development of targeted medicines,, and other privately- held companies innovating treatments for cancer, heart disease, cystic fibrosis, and other conditions.